AI algorithm for detection of cardiac amyloidosis gains FDA breakthrough device status
Related Articles
Anumana’s AI-Driven Low Ejection Fraction ECG-AI Technology Recognized in CMS 2025 OPPS Final Rule, Expanding Access to Advanced Cardiovascular Care
Company’s ECG-AI algorithm enables earlier heart failure detection{post_date: F d, Y}
Pfizer and Anumana boost detection of cardiovascular disease
Pharma Times: Artificial intelligence (AI) health technology company, Anumana, will collaborate with Pfizer to develop an artificial intelligence electrocardiogram algorithm (AI-ECG), which enables the early detection of cardiac amyloidosis.{post_date: F d, Y}
Anumana wins FDA breakthrough nod for AI algorithm that detects pulmonary hypertension
Mass Device: Anumana announced today that it received FDA breakthrough device designation for its pulmonary hypertension (PH) early detection algorithm. Cambridge, Massachusetts-based Anumana, formed by Mayo Clinic and nference and launched in…{post_date: F d, Y}
Charting a Path to the Right Diagnosis with AI Copilots
The rapid growth and widespread adoption of large language models (LLMs) across real-world applications offer a host of new opportunities for the healthcare sector. Hospitals and clinics are starting to…{post_date: F d, Y}